Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility

Addiction
Marc J FishmanGeetha A Subramaniam

Abstract

Opioid dependence is an increasing problem among adolescents and young adults, but in contrast to the standard in the adult population, adoption of pharmacotherapies has been slow. Extended-release naltrexone (XR-NTX) is a promising treatment that has been receiving increasing interest for adult opioid dependence. Clinical chart abstractions were performed on a convenience sample of 16 serial adolescent and young adult cases (mean age 18.5 years) treated for opioid dependence with XR-NTX who attended at least one out-patient clinical follow-up visit. Of these 16 cases, 10 of 16 (63%) were retained in treatment for at least 4 months and nine of 16 (56%) had a 'good' outcome defined as having substantially decreased opioid use, improvement in at least one psychosocial domain and no new problems due to substance use. These descriptive results suggest that XR-NTX in the treatment of adolescents and young adults with opioid dependence is well tolerated over a period of 4 months and feasible in a community-based treatment setting, and associated with good outcomes in a preliminary, small non-controlled case-series. This probably reflects an overall trend towards greater adoption of medication treatments for this population.

References

Jan 23, 1998·Journal of Substance Abuse Treatment·J W CornishC P O'Brien
Dec 13, 2003·Journal of Substance Abuse Treatment·Michael GossopJohn Marsden
May 22, 2004·Journal of Psychoactive Drugs·Philip ClemmeyMarc Fishman
Jun 9, 2004·Journal of Substance Abuse Treatment·Evgeny M KrupitskyGeorge E Woody
Oct 16, 2004·Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors·Andrew R MorralGreg Ridgeway
Oct 6, 2005·Archives of General Psychiatry·Lisa A MarschJohn Brooklyn
Jan 13, 2006·The Annals of Pharmacotherapy·William D Cahoon, Denise R Kockler
Nov 7, 2006·Journal of Substance Abuse Treatment·Evgeny M KrupitskyGeorge E Woody
Nov 6, 2008·JAMA : the Journal of the American Medical Association·George E WoodyPaul Fudala
Nov 6, 2008·JAMA : the Journal of the American Medical Association·David A Fiellin

❮ Previous
Next ❯

Citations

Aug 6, 2013·Paediatric Drugs·Anna PecoraroGeorge E Woody
Jan 1, 2011·Substance Abuse : Research and Treatment·Kimberly L Kjome, F Gerard Moeller
Jan 29, 2016·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Hoa T VoMarc Fishman
Feb 2, 2011·Pediatric Clinics of North America·Gabriel Kaplan, Iliyan Ivanov
Mar 10, 2016·Substance Abuse Treatment, Prevention, and Policy·Benedikt FischerJürgen Rehm
Jul 28, 2015·Games for Health Journal·Lorien C AbromsDaniel Greenberg
Sep 27, 2014·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Maria PainoPaul M Roman
Jun 25, 2016·Child and Adolescent Psychiatric Clinics of North America·Bikash SharmaMarc Fishman
Sep 11, 2016·Child and Adolescent Psychiatric Clinics of North America·Christopher J Hammond
Mar 4, 2017·Cellular and Molecular Life Sciences : CMLS·Duyilemi C AjonijebuWilliam M U Daniels
May 26, 2012·Journal of Psychopharmacology·A R Lingford-HughesUNKNOWN British Association for Psychopharmacology, Expert Reviewers Group
Mar 30, 2018·The American Journal on Addictions·Adam BisagaThomas R Kosten
Feb 13, 2018·Journal of Addiction Medicine·Jacob T BorodovskyLisa A Marsch
Jul 31, 2019·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Meredith SpadaPriya Gopalan
Mar 22, 2018·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Roxanne SaucierNabarun Dasgupta
Mar 22, 2019·Current Pediatrics Reports·Amy M YuleTimothy E Wilens
Jan 25, 2020·Focus : Journal of Life Long Learning in Psychiatry·Justine W WelshDana B Sarvey
Jun 27, 2019·Substance Abuse Treatment, Prevention, and Policy·Charles J NeighborsLiudmila Shapoval
Jan 14, 2017·Journal of Child & Adolescent Substance Abuse·Christopher J Hammond, Kevin M Gray
Sep 24, 2019·Mayo Clinic Proceedings·Tyler S OesterleMark S Gold
Aug 3, 2019·Journal of Substance Abuse Treatment·Iuliia MakarenkoFrederick L Altice
Apr 30, 2021·Early Intervention in Psychiatry·Jean Nicolas WestenbergReinhard M Krausz
Jun 3, 2021·The American Journal on Addictions·Marc FishmanEdward Nunes
Jun 13, 2021·Journal of Substance Abuse Treatment·Shannon Gwin MitchellRobert P Schwartz
Aug 16, 2021·Journal of Substance Abuse Treatment·Justine W WelshMark D Godley

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.